The Bardenas Study

A phase 2, multicenter, randomized, double masked, active comparator-controlled study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of RO7200220 in combination with ranibizumab administered intravitreally in patients with Diabetic Macular Edema.

The study aims to evaluate whether the combination of RO7200220 and ranibizumab can provide improved outcomes in terms of both efficacy and safety for patients with Diabetic Macular Edema. The combination of ranibizumab, an anti-VEGF (vascular endothelial growth factor) and RO7200220 will be administered intravitreally in one eye. The duration of the study is 18 months long.